Definity and Endoscopy abnormal - a phase IV clinical study of FDA data
Summary:
We study 5,031 people who take Definity (perflutren) or have Endoscopy abnormal. No report of Endoscopy abnormal is found in people who take Definity.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Definity?
Definity has active ingredients of perflutren. eHealthMe is studying from 4,853 Definity users. Check the latest studies of Definity.
What is Endoscopy Abnormal?
Endoscopy abnormal is found to be associated with 178 drugs and 165 conditions by eHealthMe. Check the latest studies of Endoscopy abnormal.
No report is found.
Do you take Definity and have Endoscopy abnormal?
- Check whether Endoscopy abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Definity:
- Definity (4,853 reports)
Endoscopy abnormal treatments and more:
- Endoscopy abnormal (178 reports)
How severe was Endoscopy abnormal and when was it recovered:
Expand to all the drugs that have ingredients of perflutren:
Browse all side effects of Definity:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Endoscopy abnormal:
Browse all the conditions that are associated with Endoscopy abnormal:
How the study uses the data?
The study uses data from the FDA. It is based on perflutren (the active ingredients of Definity) and Definity (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Panic Disorder and drugs of ingredients of lenalidomide - 7 seconds ago
- Could Plavix cause Reticulocyte Count Increased? - 9 seconds ago
- Remicade and Gastroesophageal Reflux Disease for Women aged 20-29 - 10 seconds ago
- Remicade and Gastrooesophageal Reflux Disease for Women aged 20-29 - 10 seconds ago
- Remicade and Reflux for Women aged 20-29 - 10 seconds ago
- Remicade and Heartburn for Women aged 20-29 - 11 seconds ago
- Remicade and Non-Cardiac Chest Pain for Women aged 20-29 - 11 seconds ago
- Remicade and Gerds for Women aged 20-29 - 11 seconds ago
- Remicade and Acid Reflux for Women aged 20-29 - 11 seconds ago
- Remicade and Reflux Esophagitis for Women aged 20-29 - 12 seconds ago